Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab

European Journal of Pediatrics

Volumn 172, Issue 4, 2013, Pages 513-518

  Fujinaga, Shuichiro ^a   Someya, Tomonosuke ^b   Watanabe, Tsuneki ^a   Ito, Akira ^a   Ohtomo, Yoshiyuki ^c   Shimizu, Toshiaki ^b   Kaneko, Kazunari ^d  

^a SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclosporine; Mycophenolate mofetil; Rituximab; Steroid dependent nephrotic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAINTENANCE THERAPY; MALE; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MALE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES; RECURRENCE; STEROIDS; TREATMENT OUTCOME;

EID: 84876687278     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-012-1913-3     Document Type: Article

References (21)

1. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and - resistant nephrotic syndrome. Pediatr Nephrol 18:833-837
2. Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794-797
3. Filler G, Huang SH, Sharma AP (2011) Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr Nephrol 26:1759-1762
4. Filler G, Lepage N (2004) To what extent dose the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr Nephrol 19:962-965
5. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K (2010) Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 25:539-544
6. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y (2006) Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child 91:666-670
7. Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K (2007) A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71-76
8. Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19:101-104
9. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269-1279
10. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and - dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5:2207-2212
11. Iijima K (2011) Rituximab for childhood refractory nephrotic syndrome. Pediatr Int 53:617-621
12. Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N (2002) Risk factors for cyclosporineinduced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61:1801-1805
13. Ishikura K, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Yata N, Ando T, Honda M (2010) Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transplant 25:3956-3962
14. Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K (2011) Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroiddependent nephrotic syndrome. Pediatr Nephrol 26:1823-1828
15. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321-1328
16. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J (2012) Longterm follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 27:1910-1915
17. Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J (2005) Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 20:914-919
18. Nakamura T, Nozu K, Iijima K, Yoshikawa N, Morita Y, Yamamori M, Kako A, Matsuo M, Sakurai A, Okamura N, Ishikawa T, Okumura K, Sakaeda T (2007) Association of cumulative cyclosporine dose with its irreversible nephrotoxicity in Japanese patients with pediatric-onset autoimmune disease. Biol Pharm Bull 30:2371-2375
19. Sairam VK, Kalia A, Rajaraman S, Travis LB (2002) Secondary resistance to cyclosporine A in children with nephrotic syndrome. Pediatr Nephrol 17:842-846
20. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T (2012) Rituximab in steroiddependent idiopathic nephrotic syndrome in childhood - follow-up after CD19 recovery. Nephrol Dial Transplant 27:1083-1089
21. Ulinski T, Dubourg L, Said MH, Parchoux B, Ranchin B, Cochat P (2005) Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20:482-485